Denali Therapeutics shares slumped for the second straight day Tuesday after the drugmaker's ALS treatment failed in a ...

The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

Denali Therapeutics' DNL343 fails to meet endpoints in the HEALEY ALS study, marking a second clinical setback for the ...

The result is another major disappointment to ALS patients, who have limited drug treatment options at present, particularly ...

Nvidia stock rises after the artificial-intelligence chip maker unveils its next generation gaming graphic cards, while ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks.

Here is a GMC Sierra owner who has a warning for truck buyers. Her Sierra truck looks great on the outside and inside, but ...

A 28-year-old Steamboat Rock woman has been charged with second-offense OWI after being found sitting in her vehicle along Hwy 20 on Dec. 9.

The state of Alaska and Alaskans themselves have always had a clear record that they prefer to call North America’s tallest ...